3.86
Schlusskurs vom Vortag:
$3.76
Offen:
$3.77
24-Stunden-Volumen:
2.98M
Relative Volume:
0.81
Marktkapitalisierung:
$1.17B
Einnahmen:
$75.13M
Nettoeinkommen (Verlust:
$-146.41M
KGV:
-7.8711
EPS:
-0.4904
Netto-Cashflow:
$-174.43M
1W Leistung:
+12.54%
1M Leistung:
+10.60%
6M Leistung:
-36.72%
1J Leistung:
+58.85%
Abcellera Biologics Inc Stock (ABCL) Company Profile
Firmenname
Abcellera Biologics Inc
Sektor
Branche
Telefon
(604) 559-9005
Adresse
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
ABCL
Abcellera Biologics Inc
|
3.86 | 1.14B | 75.13M | -146.41M | -174.43M | -0.4904 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-02-28 | Eingeleitet | Cowen | Outperform |
| 2022-12-15 | Eingeleitet | Goldman | Buy |
| 2022-11-16 | Eingeleitet | Truist | Buy |
| 2021-12-21 | Eingeleitet | The Benchmark Company | Buy |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-01-05 | Eingeleitet | Berenberg | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-05 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | Stifel | Buy |
Alle ansehen
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock ahead of 2H26 data - Investing.com
Truist reiterates Buy on AbCellera stock ahead of 2H26 data By Investing.com - Investing.com Canada
Truist reiterates Buy on AbCellera stock, eyes 2H26 data readout - Investing.com
Biotech Penny Stocks Rally OABI ABCL PACB 2026 - Gotrade
Is Jones Trading’s New Coverage of AbCellera (ABCL) Reframing Its Clinical-Stage Platform Narrative? - Yahoo Finance
AbCellera Biologics (ABCL) Committed to Leverage Differentiated Technology for Drug Discovery - Insider Monkey
Is AbCellera Biologics Inc affected by consumer sentimentWall Street Watch & Free High Return Stock Watch Alerts - baoquankhu1.vn
Wall Street Bullish on AbCellera Biologics Inc. (ABCL), Here’s Why - MSN
Portfolio Recap: Is AbCellera Biologics Inc part of any ETFMarket Activity Summary & Precise Swing Trade Alerts - baoquankhu1.vn
Insider Sell: What hedge funds are buying AbCellera Biologics Inc2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
AbCellera Biologics Inc (HAM:8QQ) Stock Price & 30 Year Financial Data - GuruFocus
AbCellera (ABCL): Among the stocks that could 10x over the next 5 years - MSN
AbCellera Biologics Initiated at Buy by Jones Trading - Moomoo
AbCellera Biologics (ABCL): New 'Buy' Rating from Jones Trading - GuruFocus
AbCellera Biologics (ABCL): New 'Buy' Rating from Jones Trading | ABCL Stock News - GuruFocus
Jones Trading initiates coverage of AbCellera Biologics (ABCL) with buy recommendation - MSN
JonesTrading Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $11 - Moomoo
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Aug Big Picture: What is AbCellera Biologics Incs P E ratio telling usTrade Ideas & Accurate Buy Signal Notifications - baoquankhu1.vn
Insider Stock Buying Reaches US$1.04m On AbCellera Biologics - Moomoo
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $3.52 - Moomoo
Press Releases about AbCellera Biologics Inc.Common Shares (Nasdaq:ABCL) - FinancialContent
ABCL Technical Analysis | Trend, Signals & Chart Patterns | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
What sparked AbCellera Biologics to soar over 9% after hours - MSN
AbCellera Biologics Inc. (ABCL) stock price, news, quote and history - Yahoo Finance UK
AbCellera Biologics Inc. (ABCL) Stock Price, News, Quote & History - Yahoo! Finance Canada
AbCellera (ABCL): Among the Stocks That Could 10x Over the Next 5 Years - Insider Monkey
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - PharmiWeb.com
Press Release: AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 - 富途牛牛
5 Stocks That Could 10X Over the Next 5 Years - Insider Monkey
Aug Gainers: Why is AbCellera Biologics Inc stock going down2026 Final Week & AI Driven Stock Reports - baoquankhu1.vn
ABCL SEC FilingsAbcellera Biologics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Update Report: What is AbCellera Biologics Incs P E ratio telling usTrade Signal Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Tudor Investment Corp ET AL Makes New Investment in AbCellera Biologics Inc. $ABCL - MarketBeat
AbCellera: Dart-Board Approach Reflects Trading Premium (Upgrade) (NASDAQ:ABCL) - Seeking Alpha
Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
AbCellera Biologics Inc. (ABCL) - minichart.com.sg
Aug Intraday: Is AbCellera Biologics Inc affected by consumer sentiment - baoquankhu1.vn
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum - MarketBeat
Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):